CUE logo

CUE Cue Biopharma, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$4.50
-0.26 (-5.46%)

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion prote…

Market Cap: $32.69Mwww.cuebiopharma.com

Price

No data yet.

Social Signal Score

53
5d
—
30d
50
1 mentions
—
60d
50
2 mentions
—
90d
58
5 mentions
—
news: 5

Analyst Ratings

9 analysts
Buyconsensus
Strong Buy 0Buy 9Hold 0Sell 0Strong Sell 0
Avg price target$83+1744.4%
Low $83Median $83High $83
Current Consensus

Revenue

$132.0K
$0.00$7.31M$14.63M$21.94M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-12.00
$-16.27–$-9.12
1 analysts
FY2026
$-23.95
$-32.47–$-18.21
1 analysts
FY2027
$-6.20
$-8.40–$-4.71
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Shao-Lee Lin
Sector
Healthcare
Industry
Biotechnology
Employees
29
Beta
2.81
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
-16.93
www.cuebiopharma.com